Literature DB >> 10564512

Elevated levels of polyamines and trypanothione resulting from overexpression of the ornithine decarboxylase gene in arsenite-resistant Leishmania.

A Haimeur1, C Guimond, S Pilote, R Mukhopadhyay, B P Rosen, R Poulin, M Ouellette.   

Abstract

The levels of trypanothione, a glutathione-spermidine conjugate, are increased in the protozoan parasite Leishmania selected for resistance to the heavy metal arsenite. The levels of putrescine and spermidine were increased in resistant mutants. This increase is mediated by overexpression of ornithine decarboxylase (ODC), the rate-limiting enzyme in polyamine biosynthesis. Gene overexpression is generally mediated by gene amplification in Leishmania but, here, the mRNA and the enzymatic activity of ODC are increased without gene amplification. This RNA overexpression is stable when cells are grown in the absence of the drug and does not result from gene rearrangements or from an increased rate of RNA synthesis. Transient transfections suggest that mutations in the revertant cells contribute to these elevated levels of RNA. Stable transfection of the ODC gene increases the level of trypanothione, which can contribute to arsenite resistance. In addition to ODC overexpression, the gene for the ABC transporter PGPA is amplified in the mutants. The co-transfection of the ODC and PGPA genes confers resistance in a synergistic fashion in partial revertants, also suggesting that PGPA recognizes metals conjugated to trypanothione.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10564512     DOI: 10.1046/j.1365-2958.1999.01634.x

Source DB:  PubMed          Journal:  Mol Microbiol        ISSN: 0950-382X            Impact factor:   3.501


  46 in total

1.  Intracellular localization of the ABCC proteins of Leishmania and their role in resistance to antimonials.

Authors:  Philippe Leprohon; Danielle Légaré; Marc Ouellette
Journal:  Antimicrob Agents Chemother       Date:  2009-03-23       Impact factor: 5.191

2.  Reduced antimony accumulation in ARM58-overexpressing Leishmania infantum.

Authors:  Carola Schäfer; Paloma Tejera Nevado; Dorothea Zander; Joachim Clos
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

Review 3.  ABC proteins of Leishmania.

Authors:  D Légaré; S Cayer; A K Singh; D Richard; B Papadopoulou; M Ouellette
Journal:  J Bioenerg Biomembr       Date:  2001-12       Impact factor: 2.945

Review 4.  Drug resistance in leishmaniasis.

Authors:  Simon L Croft; Shyam Sundar; Alan H Fairlamb
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

Review 5.  Antimony transport mechanisms in resistant leishmania parasites.

Authors:  Frédéric Frézard; Rubens Monte-Neto; Priscila G Reis
Journal:  Biophys Rev       Date:  2014-01-25

6.  Gene expression analysis of the mechanism of natural Sb(V) resistance in Leishmania donovani isolates from Nepal.

Authors:  Saskia Decuypere; Suman Rijal; Vanessa Yardley; Simonne De Doncker; Thierry Laurent; Basudha Khanal; François Chappuis; Jean-Claude Dujardin
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

Review 7.  Leishmania antimony resistance: what we know what we can learn from the field.

Authors:  Khatima Aït-Oudhia; Elodie Gazanion; Baptiste Vergnes; Bruno Oury; Denis Sereno
Journal:  Parasitol Res       Date:  2011-07-29       Impact factor: 2.289

8.  Antimony resistance and trypanothione in experimentally selected and clinical strains of Leishmania panamensis.

Authors:  Diego A Goyeneche-Patino; Liliana Valderrama; John Walker; Nancy G Saravia
Journal:  Antimicrob Agents Chemother       Date:  2008-09-29       Impact factor: 5.191

9.  Drug resistance in leishmaniasis.

Authors:  Jaya Chakravarty; Shyam Sundar
Journal:  J Glob Infect Dis       Date:  2010-05

10.  A new ABC half-transporter in Leishmania major is involved in resistance to antimony.

Authors:  J I Manzano; R García-Hernández; S Castanys; F Gamarro
Journal:  Antimicrob Agents Chemother       Date:  2013-05-28       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.